| Year |
Citation |
Score |
| 2012 |
Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discovery. 2: 450-7. PMID 22588882 DOI: 10.1158/2159-8290.Cd-11-0287 |
0.468 |
|
| 2010 |
Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science Translational Medicine. 2: 16ra7. PMID 20371474 DOI: 10.1126/Scitranslmed.3000389 |
0.626 |
|
| 2009 |
Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2311-22. PMID 19318475 DOI: 10.1158/1078-0432.Ccr-08-2533 |
0.497 |
|
| 2008 |
Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology. 4: 691-9. PMID 18849971 DOI: 10.1038/Nchembio.117 |
0.683 |
|
| 2007 |
Blair JA, Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA, Shokat KM. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology. 3: 229-38. PMID 17334377 DOI: 10.1038/Nchembio866 |
0.709 |
|
| 2007 |
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445: 437-41. PMID 17206155 DOI: 10.1038/Nature05474 |
0.683 |
|
| Show low-probability matches. |